Psilocybin, the psychoactive compound in magic mushrooms, may be integrated into healthcare settings. George Winter examines the potential for using psilocybin administration as a therapeutic tool, likely for mental health conditions, though the abstract does not specify particular outcomes or populations.
Dextromethorphan-bupropion shows promise for treatment-resistant depression (TRD) in a small sample of 52 patients, with 27 experiencing improvement within 2 weeks and 43 achieving remission after 2 months. The authors advocate for integrating novel antidepressants into TRD management guidelines, noting limitations including a medically underserved demographic and small sample size. They caution that results require further research.